NasdaqCM:BMRA

Stock Analysis Report

Executive Summary

Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions.

Snowflake

Fundamentals

High growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has Biomerica's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

6.5%

BMRA

1.7%

US Medical Equipment

2.3%

US Market


1 Year Return

11.1%

BMRA

10.1%

US Medical Equipment

5.6%

US Market

Return vs Industry: BMRA exceeded the US Medical Equipment industry which returned 10.1% over the past year.

Return vs Market: BMRA exceeded the US Market which returned 5.6% over the past year.


Shareholder returns

BMRAIndustryMarket
7 Day6.5%1.7%2.3%
30 Day2.5%-1.7%-1.0%
90 Day14.6%-1.7%-0.7%
1 Year11.1%11.1%11.0%10.1%7.9%5.6%
3 Year18.3%18.3%70.4%65.2%45.6%36.3%
5 Year288.2%288.2%128.5%103.2%65.8%47.6%

Price Volatility Vs. Market

How volatile is Biomerica's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Biomerica undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Undervalued: BMRA ($3.3) is trading below our estimate of fair value ($27.09)

Significantly Undervalued: BMRA is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: BMRA is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: BMRA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate BMRA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: BMRA is overvalued based on its PB Ratio (8x) compared to the US Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is Biomerica forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

69.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BMRA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: BMRA is forecast to become profitable over the next 3 year, which is considered above average market growth.

High Growth Earnings: BMRA's loss is forecast to worsen by 0% next year.

Revenue vs Market: BMRA's revenue (39.9% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: BMRA's revenue (39.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if BMRA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Biomerica performed over the past 5 years?

-39.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: BMRA is unprofitable, and losses have increased over the past 5 years at a rate of -39.7% per year.

Accelerating Growth: Unable to compare BMRA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BMRA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: BMRA has a negative Return on Equity (-60.11%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: BMRA is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: BMRA is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Biomerica's financial position?


Financial Position Analysis

Short Term Liabilities: BMRA's short term assets ($4.5M) exceeds its short term liabilities ($1.3M)

Long Term Liabilities: BMRA has no long term liabilities


Debt to Equity History and Analysis

Debt Level: BMRA is debt free.

Reducing Debt: BMRA has not had any debt for past 5 years.


Balance Sheet

Inventory Level: BMRA has a high level of physical assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if BMRA's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BMRA has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: BMRA has less than a year of cash runway if free cash flow continues to reduce at historical rates of -66% each year


Next Steps

Dividend

What is Biomerica's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate BMRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate BMRA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if BMRA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BMRA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BMRA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Biomerica's salary, the management and board of directors tenure and is there insider trading?

16.3yrs

Average board tenure


CEO

Zackary Irani (53yo)

22.5yrs

Tenure

US$328,906

Compensation

Mr. Zackary S. Irani has been Chairman of the Board and Chief Executive Officer of Biomerica Inc. since April 29, 1997 and served as its President. Mr. Irani serves as the President and Chairman of ReadySc ...


CEO Compensation Analysis

Compensation vs. Market: Zackary's total compensation ($USD328.91K) is about average for companies of similar size in the US market ($USD493.00K).

Compensation vs Earnings: Zackary's compensation has increased whilst the company is unprofitable.


Board Age and Tenure

16.3yrs

Average Tenure

65yo

Average Age

Experienced Board: BMRA's board of directors are seasoned and experienced ( 16.3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Janet Moore (68yo)

    CFO, Treasurer

    • Tenure: 22.5yrs
    • Compensation: US$146.68k
  • Zackary Irani (53yo)

    Chairman & CEO

    • Tenure: 22.5yrs
    • Compensation: US$328.91k

Board Members

  • Ned Barnholt (75yo)

    Chairman of Strategic Advisory Board

    • Tenure: 0yrs
  • Janet Moore (68yo)

    CFO, Treasurer

    • Tenure: 22.5yrs
    • Compensation: US$146.68k
  • Zackary Irani (53yo)

    Chairman & CEO

    • Tenure: 22.5yrs
    • Compensation: US$328.91k
  • Francis Cano (72yo)

    Director

    • Tenure: 20.3yrs
    • Compensation: US$42.77k
  • Mark Sirgo (65yo)

    Director

    • Tenure: 3.3yrs
    • Compensation: US$42.77k
  • Allen Barbieri (61yo)

    Director

    • Tenure: 20yrs
    • Compensation: US$61.10k
  • Harry Leider

    Member of Strategic Advisory Board

    • Tenure: 1.5yrs
  • Jane Emerson (65yo)

    Director

    • Tenure: 12.5yrs
    • Compensation: US$52.77k
  • Tony Lembo

    Member of Scientific Advisory Board

    • Tenure: 3.3yrs

Company Information

Biomerica, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Biomerica, Inc.
  • Ticker: BMRA
  • Exchange: NasdaqCM
  • Founded: 1971
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$32.402m
  • Shares outstanding: 9.82m
  • Website: https://www.biomerica.com

Number of Employees


Location

  • Biomerica, Inc.
  • 17571 Von Karman Avenue
  • Irvine
  • California
  • 92614
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BMRANasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 1975

Biography

Biomerica, Inc., together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions. The compa ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 23:32
End of Day Share Price2019/10/16 00:00
Earnings2019/05/31
Annual Earnings2019/05/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.